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Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease of unknown aetiology, leading to progressive damage
of bone and cartilage with functional impairment and disability. Whilst the synovial membrane represents the epicentre of
the immune-inflammatory process, there is growing evidence indicating the potential involvement of additional anatomical
compartments, such as the lung, bonemarrow, and secondary lymphoid tissues. Draining lymphnodes represent the elective site for
tissue immune-surveillance, for the generation of adaptive immune responses and a candidate compartment for the maintenance
of peripheral tolerance. Despite the precise role of the juxta- and extra-articular lymph node stations in the pathogenesis of RA
remaining poorly defined, several lines of research exploiting new technological approaches are now focusing on their assessment
as a potential new source of pathobiologic information, biomarkers, and complementary therapeutic targets. In this review we
present an updated overview of the main concepts driving lymph node research in RA, highlighting the most relevant findings,
current hypothesis, and translational perspectives.
1. Introduction
In chronic inflammatory and autoimmune diseases, the
cross-talk and reciprocal modulation between peripheral and
lymphoid tissues represent an integral part in the develop-
ment, maintenance and progression of undesired immune
responses. Studies using the nonobese diabetic (NOD)mouse
model of autoimmune diabetes have shown that islet-cell
antigens are presented to autoreactive T cells within the pan-
creatic draining lymph nodes (LNs) [1], and early LN excision
protects mice against insulin autoantibodies, insulitis, and
diabetes development [2]. Upon initiation of inflammation,
cellular and molecular trafficking between the periphery
and the draining LNs through the expanded lymphatic
vascular network significantly influences the progression of
the inflammatory response by modulating the degree of
tissue infiltration and shaping the immune response [3–5].
Recent experimental studies in animal models have indeed
shown that pharmacological manipulation of the peripheral
tissue-LN connection might represent a novel therapeutic
strategy for inflammatory disorders [6–8]. Altogether, the
above observations indicate that peripheral tissues and drain-
ing LNs operate as a functional unit during chronic inflam-
mation, and full understanding of how local pathological pro-
cesses originate and progress cannot disregard the analysis of
the tight interconnection and reciprocal modulation between
the two compartments.
Rheumatoid arthritis (RA) is a complex autoimmune
disorder that primarily targets the synovium of diarthrodial
joints. Cell-cell and cytokine networks established within the
inflamed RA synovium sustain disease chronicity, amplify
autoimmune responses and ultimately elicit cartilage and
bone destruction [9–11]. Synovial pathobiology has offered
crucial guidance for the development of efficacious therapeu-
tics and still remains a rich source of investigation for the
advancement in the biological and clinical understanding of
RA [12–14]. Consistent data have however now established
that the synovial compartment is neither the initiator nor
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the sole player of RA.The identification that systemic autoim-
munity may antedate the onset of clinical arthritis by several
years [15, 16], and synovial involvement does not appear
prominent until the later stages of disease development [17–
20], has redirect interest towards possible extra-articular sites
of origin of RA-associated immunological disturbances, such
as mucous membrane sites of the respiratory and gastroen-
teric tract as well as the oral cavity [21–24]. Furthermore,
despite synovial involvement remains the cardinal feature
of clinical RA, other joint compartments appear at least
as affected in course of the disease. The subchondral bone
marrow adjacent to inflamed joints indeed undergoes inflam-
matory changes since the earliest phases of RA [25, 26], and
marrow inflammation appears intimately linked with synovi-
tis and subsequent pathologic bone remodeling [27, 28].
Collectively, compared to organ-specific autoimmune
conditions, in which the autoimmune reaction targets a
particular organ via a humoral and/or cellular response
against specific autoantigens since the very early phases of
the disease, the pathogenic processes of RA thus appear to
originate and progress in a variety of anatomical districts.
Such complexity, together with the lack of knowledge of
the target autoantigen(s), makes the analysis of local and
systemic lymphoid tissue reactions particularly challenging
in RA. Experimental animal models of arthritis and the
introduction of imaging techniques capable of evaluating LN
responses in humans have only recently opened a window
onto the possible participation of the lymphoid compartment
to RA. In this review, we present an updated summary of
the main findings related to LN involvement and potential
pathobiologic role in course of chronic arthritis. To provide
a contextualized framework of the anatomical concepts,
functional processes and imaging findings that have been
the object of analysis in pathological settings, the review
is introduced by a brief summary of the general structural
features of the homeostatic LN and of the main structural
changes induced by immunological challenges under con-
trolled experimental conditions.
2. Lymph Node Homeostatic Structure
LN are encapsulated oval-shaped fibrovascular organs, strate-
gically distributed through the body of mammals, that rep-
resent the elective site for lymph filtration, antigen surveil-
lance, antigen-presenting cell (APC)-lymphocyte interac-
tions, effector/memory cell generation and antibody secre-
tion. These functions are favored by the dynamic structure
of the LN, capable of integrating cell trafficking from the
bloodstream, drainage of cells and soluble factors from
peripheral tissues through the afferent lymphatic system and
effector cell/molecule output from the efferent lymph.
The anatomical and functional nodal unit is the lym-
phoid lobule, a polarized structure that can be schemat-
ically subdivided into three main areas with specific and
complementary roles: (1) an apex, consisting of the B cell
rich superficial cortex, where B lymphocytes can interact
with resident follicular dendritic cells (FDCs) and undergo
affinity maturation within germinal centres (GCs), (2)
a deep paracortex, characterized by paracortical cords where
T lymphocytes can interact and establish cognate interactions
with antigen-loaded dendritic cells and (3) a base, or nodal
medulla, consisting of medullary cords, where plasma cell
precursors derived from theGC responsemigrate andmature
into antibody-secreting plasma cells [29].
Functional communication between the above described
areas and the periphery is guaranteed by lymph-filled sinuses,
interconnected structures surrounding lymphoid lobules: the
subcapsular sinus associated with the afferent lymphatics
at the LN apex (conveying dendritic cells from peripheral
tissues to the paracortex), the transverse sinuses, and the
paracortical-medullary sinuses ending with the efferent lym-
phatic vessel at the hilum (the output route of cells returning
to the systemic circulation) [29]. The complementary path
of LN cell trafficking takes place from the bloodstream
through high endothelial venules (HEV), specialized ves-
sels diffusely distributed within the nodal cortex, which
allow na¨ıve lymphocyte recirculation and local immune-
surveillance through constitutive expression of addressins
and homeostatic chemokines [30]. In the same LN area, a
reticular network comprising reticular fibers, extracellular
matrix components and stromal fibroblastic reticular cells
(FRC) provides a three dimensional scaffold (the nodal con-
duit system) connected to both the parenchymal lymphatic
apparatus and the peri-HEV space.This scaffold guarantees a
close microanatomical connection between the nodal blood
vascular apparatus and lymphatic network and the infrastruc-
ture for antigen and soluble substances transport within the
LN parenchyma [30, 31].
3. Lymph Node Structural Changes during
Experimental Immune-Inflammatory
Challenge
Upon immune-inflammatory challenges, the homeostatic
architecture and processes described in the previous section
are subjected to modifications that lead to specific changes
involving both the lymphocytic and the stromal component.
These changes are collectively referred to as LN reactivity, a
dynamic process involving induction and resolution phases,
essentially aimed at the eradication of the triggers and return
to homeostasis.
One of the most traceable pieces of evidence of reactivity
is LNhypertrophy, the clinical sign andmacroscopic outcome
of a series of biological modifications, partly dependent on
lymphotoxin𝛽 receptor (LT𝛽R) signaling and the TNF ligand
superfamily member 14 (TNFSF14/LIGHT) [32], inducing
dramatic changes in local leukocyte trafficking, expansion
of the fibroblastic stromal network [33, 34], and LN hyper-
cellularity. The former changes include increased mobi-
lization of mature dendritic cells from peripheral tissues
through the afferent lymphatics, increased recruitment of
lymphocytes from the bloodstream, and transient reduction
of leukocyte egress from the efferent lymph, a phenomenon
conventionally defined as LN “shut-down” [35]. Collectively,
these events are instrumental in facilitating the encounter of
antigen-loaded APCs with rare circulating antigen-specific
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lymphocytes as well as the intercellular cooperation between
antigen-specific T and B cells, a process required for the
initiation of the T cell dependent GC, one of themost evident
signs of the ongoing adaptive response within a reactive LN
[29].
Whilst changes in cellular input to the node are in
part mediated by changes in HEV molecular activation
[30], LN reactivity can also lead to the early and reversible
modification of local blood flow supply and LN micro-
angioarchitecture. Data supporting these concepts, which
have prompted recent efforts aimed at tracking human LN
reactivity through ultrasonographic assessments of local vas-
cularity (see Section 5) [36], come from independent analyses
performed over the last four decades demonstrating the effect
of immune-inflammatory challenges on the enhancement
of LN blood flow [37, 38] through remodeling of the feed
arteriole [39], and on the upregulation of nodal angiogenesis
[40, 41] through a mechanism involving FRC-derived vascu-
lar endothelial growth factor (VEGF) and CD11c+ dendritic
cells [42, 43].
In parallel with the described modifications of the blood
vascular system, the reactive LN can also undergo substantial
changes in the local lymphatic apparatus and lymphatic
drainage, processes that are now the object of growing
attention in the field of chronic inflammatory diseases as
potential check-points of peripheral pathology control (see
Section 4). For decades the lymphatic network has been
indeed considered as an inert drainage system. However,
it is now clear that lymphatic vessels (both in peripheral
tissues and in the LN) are actually highly dynamic structures,
tightly regulated and actively implicated in the regulation
of downstream immunological events. Fundamental studies
elucidating the dynamic behavior of nodal lymphatic vessels,
its mechanistic bases and immunological outcomes have
been carried out by independent groups in recent years
demonstrating the expansion of the LN lymphatic apparatus
(with vessel proliferation) after local immunization [44], the
coregulated expansion of LN blood/lymphatic vessels by the
sequential activity of CD11c+ dendritic cells and lymphocytes
[33], and the downstream enhancing effect of this process on
local migration of dendritic cells [44]. As inferred by time-
course analyses following LN experimental challenge inmice,
both blood vessel proliferation and lymphatic system expan-
sion in reactive LN have been shown to be spontaneously
reversible in vivo [40, 45, 46], pointing at the existence of
postreactivity regulatory steps, physiologically instrumental
in the reestablishment of LN stroma homeostasis.
4. Lymph Node Involvement and
Pathobiologic Role in Chronic
Arthritis Models
Indubitably, full understanding of LN responses following
experimental immunization represents an essential step to
provide a rationale biologic platform for the development
of LN research in humans. However, to what extent does
experimental manipulation fully recapitulate the dynamics
of LN challenge in chronic inflammatory settings remains
the object of intense investigation. In particular, for what
concerns RA, there are at least three issues that need to
be taken into account: (1) the chronicity of the peripheral
inflammatory process, which may last for months (at least
at subclinical level), leading to potential exhaustion of LN
responsemechanisms acting in course of acute inflammation,
(2) the lack of knowledge regarding the nature and anatomic
distribution of the primary triggers of the dysregulated
immunological response, whose activation may be ubiqui-
tous or tissue-specific, transient or intermittent, unrespon-
sive to conventional treatments or subjected to therapeutic
interference, and (3) the unique pathologic features of the
inflammatory process that can lead to massive hypertrophy
of the target tissues with potential unbalance in draining
LN response capacity during the progression of the disease.
Due to the intrinsic difficulties and ethical limitations in
assessing the functional and dynamic properties of the LN
compartment in course of human disease, animal models
of chronic (autoimmune) arthritis represent therefore a
fundamental tool to advance mechanistic knowledge in the
field.
The main aspects of RA pathology that could be sup-
ported by the activity or by a defective function of peripheral
nodes can be summarized into three, nonmutually exclusive,
points: (1) the local generation of autoimmune responses,
(2) the maintenance of peripheral tolerance, and (3) the
regulation of the peripheral inflammatory status through
drainage of cells and fluids [10].
Compelling evidence supporting the possible contri-
bution of the LN in the generation and perpetuation of
arthritogenic autoimmunity has been provided by Mandik-
Nayak et al. [47].The authors carried out a systematic analysis
of the autoimmune response in secondary lymphoid tissues of
K/BxN mice, a murine model generated by crossing KRN T
cell receptor transgenic (Tg) mice on a C57BL/6 background
with NOD mice. K/BxN mice develop arthritis at 1 month
of age and generate spontaneous responses against the ubiq-
uitous autoantigen glucose-6-phosphate-isomerase (GPI). By
tracking the anti-GPI B cell response in different anatomic
sites at different stages of the disease (preclinical, acute, and
chronic), the authors could demonstrate, in parallel with
arthritis onset and appearance of serum autoantibodies, the
localization of anti-GPI+ B cells (and differentiation of anti-
GPI secreting B cells) within GCs and medullary cords of
peripheral reactive LNs. Of note, despite ubiquitous autoanti-
gen expression, the autoimmune response was shown to
start specifically in the LN draining target joints, spreading
thereafter to other lymphoid stations including the spleen.
Alongside highlighting the early role of peripheral lymphoid
tissues in a model of systemic arthritogenic autoimmunity,
these data pointed out also at the potential relevance of the
juxta-articular lymphoid stations in the pathogenic cascade
of the inflammatory process.
In keeping with this concept, the dynamics and regulators
of the joint-draining LN functional unit in course of arthritis
have been the object of intense investigation in recent years,
with increasing attention also on nonimmunological aspects.
Several studies in this direction have been performed in
the TNF-transgenic system, a bona fide adaptive immune
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response-independent model of arthritis, starting in the
ankles, with subsequent heterogeneous involvement of the
knees, preceded by dynamic changes in popliteal LN volume,
blood flow, and lymphatic sinuses’ size [48–50]. Despite the
absence of detectable signs of B cell immune-reactivity, as
inferred by the lack of activation-induced cytidine deami-
nase (AID) and Blimp-1 upregulation [51], initial evidence
supporting a role of the draining LN in this system has
been provided by Proulx et al. [49]. Through prospective,
contrast-enhanced magnetic resonance imaging (CE-MRI)
studies, the authors could demonstrate the significant nega-
tive correlation between popliteal LN size/lymphatic drainage
capacity and progression of ipsilateral knee synovitis during
the spontaneous course of the disease. Direct proof of these
concepts has been subsequently obtained by gain-loss of
function experiments in the same mouse strain showing,
through VEGFR-3 blockade and VEGF-C intra-articular
gene transfer, the protective effect of lymphatic drainage
to the popliteal LN on local synovitis, bone erosions and
cartilage loss [52, 53].
The observed heterogeneity of popliteal LN draining
capacity, and its recognized pathophysiologic relevance dur-
ing the spontaneous course of the disease in TNF transgenic
mice, has led to further studies aimed at characterizing the
cellular regulatory mechanisms of these processes. In this
context, a relevant observation has been the identification of
the potential antibody-independent role of nodal B cells [54]
on the mechanical control of LN lymphatic flow. Evidence
supporting this hypothesis derives from the work performed
by Li et al. [51, 55] who, through time-course assessments
of TNF-transgenic arthritis progression, could demonstrate
the existence of an LN “collapse” phase, a postexpansion
phase tightly coupledwith worsening of arthritis in ipsilateral
joints. LN “collapse” is characterized by LN volume con-
traction, disruption of nodal microarchitecture with massive
B cell translocation into paracortical sinusoidal spaces, and
reduction of local lymphatic drainage. Direct support to this
mechanistic model and to its potential clinical relevance
has been provided by response to treatment studies with
B cell depleting agents, showing the efficacy of anti-CD20
monoclonal antibodies on the depletion of LN B cells, and its
unexpected positive effect on the increase of LN lymphatic
drainage with reduction in ipsilateral synovitis [51, 56].
To what extent (i) is the process of B-cell driven LN
“collapse” a generalized feature of LN reactivity to immune-
inflammatory challenge (see previous section) or is a specific
response to chronic inflammation and (ii) whether these
dynamics can be applied to humandisease and treatment, still
remain to be defined.
5. Evidence of Lymph Node Involvement in
Patients with Rheumatoid Arthritis
Clinically, LN involvement in patients with RA is well
established, and lymphadenopathy is consistently recognized
among the possible extra-articular manifestations of the
disease [57]. Since its first description accredited to Chauffard
and Ramond in 1896, LN enlargement has been repeatedly
confirmed in historical case series of the first half of the last
century, with a frequency of detection ranging from 19% to
96% [58]. Despite the clinical interest in RA lymphadenopa-
thy has diminished over the years due to the nonthreatening
nature of the condition, earlier studies on the extra-articular
features of RA report equally variable frequencies. Palpable
LNs were detected in 41% of 102 British patients within
the first 4-5 years from disease onset [59] and in 1.7% of
587 Italian RA patients with short disease duration (9.6 ±
8.6 months) [60]. The extreme variability reported in the
literature could be attributed to several factors, including
differences in the clinical features of the subjects analyzed,
heterogeneous disease duration, geographic variations, and
sites and modality of LN evaluation.
Histologically, lymphadenopathy associatedwithRAusu-
ally demonstrates reactive follicular hyperplasia and poly-
clonal plasma cell infiltration in the interfollicular area [61–
63] as well as increased GCs with high B cell activity
[64]. A moderate degree of vascular proliferation has also
been reported [65]. Compared with nonrheumatoid follic-
ular hyperplasia, the LNs in patients with active RA show
increased numbers of CD8+ T lymphocytes in GCs and
reduced IL-2R+ cells in the paracortex, possibly due to active
recirculation of activated lymphocytes within the inflamed
synovium [63]. Supporting that such morphological features
may reflect active involvement of LNGCs in the generation of
autoimmune responses typical of RA, LN areas occupied by
follicles were described to correlate with rheumatoid factor
(RF) status and titres [63]. More directly, Mellors et al. [66],
by incubating RA axillary LNs with fluorescent agglutinated
𝛾-globulins, reported the presence of RF inGC-localized cells
and plasma cells in one out of ten GCs from a seropositive RA
patient with active disease. These studies were confirmed 30
years later by Imai et al. [67], who demonstrated the presence
of IgM RF in the LNs of seven out of seven seropositive
patients but not in normal controls.
A critical question that remains unsolved is whether the
LN compartment represents a primary site for the generation
of initial autoimmune responses leading to RA. Incidentally,
the occurrence of LN reactive hyperplasia before the onset
of joint symptoms was already documented in historical
studies performed in healthy subjects with unexplained
lymphadenopathy [62]. More recently, the development of
ultrasound-guided LN biopsy sampling procedures has con-
siderably expanded the possibility of more systematic studies
aimed at analyzing the early pathologic changes eventually
occurring in healthy subjects at risk of developing RA [68].
In this direction, van Baarsen et al. [69] have investigated the
cellular composition of inguinal LNs in individuals positive
for RF and/or anticitrullinated protein antibodies (ACPA), in
early arthritis patients and in autoantibody-negative healthy
controls. The LN specimens were analyzed by multicolour
flow cytometry to study different T andB lymphocyte subsets.
In this exploratory study, the authors could recognize more
CD19+ B cells and activated CD69+ CD8+ T cells in early
arthritis patients and a trend toward increased CD19+ B
cells in at risk subjects compared with controls. Together
with the reciprocal low B cell signature already described
in the peripheral blood [70], these findings have suggested
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the hypothesis that B cells may be retained within the LNs in
the earliest phases of the disease [69].
As summarized in Section 4, recent studies in animal
models of arthritis have highlighted the potential specific
role of the juxta-articular LN stations in modulating the
inflammatory cascade through immunological and nonim-
munological functions. To what extent does the regional rela-
tionship between the lymphoid and the articular compart-
ment through the afferent lymphatic system impact disease
activity in humans is however unknown. Clinically, palpable
LNs in patients with RA appear in anatomical relation
with actively involved joints. Based on a clinical survey of
100 RA patients and 100 age- and sex-matched controls,
Robertson et al. [58] reported a higher incidence of inguinal,
axillary, and epitrochlear but not cervical lymphadenopathy
in RA compared with controls, with mean joints scores
of hands and wrists significantly higher in patients with
palpable epitrochlear glands [58]. More recent studies have
confirmed that, compared to systemic autoimmune diseases
in which LN enlargement is more generalized, palpable LNs
in active RA are more frequently located in the axillary area
draining the hand joints, and clinical remission is paralleled
by LNs disappearance/reduction [71]. Sporadic reports on
positron emission tomography (PET) imaging in patients
with active RA lend further support to clinical findings,
confirming that LN uptake mostly corresponds to involved
joints [72–74]. Furthermore, in keeping with MRI studies
in animal models, the number and the size of draining LNs
were shown to cross-sectionally correlate with the inflamed
synovial volume at the knee through contrast enhanced
three-dimensional-fast spoiled gradient echo (3D-FSPGR)
MRI [75]. Although a more specific characterization of the
cellular, molecular, and fluid recirculation across the articular
and the LN compartments would require additional insights,
the analysis of prenodal lymph from the foot of RA patients
has revealed high lymph concentrations of cytokines and
chemokines exceeding those in serum, supporting their
local production within peripheral inflamed tissues [76].
Collectively, the above observations thus indicate that a
reciprocal relationship between inflamed peripheral joints
and the draining LNs can be also established in course of
human arthritis.
In this context, a challenging issue still remains the
full understanding of the temporal dynamics and anatomic
distribution of (draining) LN involvement across the different
phases of the disease, an objective that would require reliable
and noninvasive methods of LN evaluation for serial and
systemic analyses. Imaging studies performed in the oncol-
ogy field have shown that power doppler ultrasonography
(PD-US) allows sensitive assessment of the nodal structure
andmacrovessel architecture [77], which typically undergoes
extensive remodeling upon immune-inflammatory stimula-
tion (see Section 3). Using this approach, our group could
recently show that subclinical changes such as vascular flow
modulation and cortical hypertrophy are detectable in axil-
lary LNs in patients with active RA, and that these parameters
can be monitored prospectively in clinical settings [36]. The
validation of reliable assessment techniques with noninvasive
imaging approaches might open the possibility of compara-
tive and multicompartment analysis of local disease activity
in patients with RA.
6. Research Perspectives
The data presented in the previous sections of this review
support the role of the LN as a potential relevant component
of arthritis pathology, opening the attracting perspective of
extending our research focus to this anatomic compartment
as a complementary tool for the implementation of current
prognostic biomarkers, the definition of preventive strategies,
as well as the development of novel therapeutic approaches
(Figure 1). The same data, however, also point at the signifi-
cant gaps that still characterize current knowledge in the field
with specific reference to the biology, functional dynamics,
and hierarchical role of the LN compartment in human
disease, both in its preclinical phases and in its established
stage.
6.1. Autoimmunity and Peripheral Tolerance. In this regard,
one of the most critical issues (from both a rheumatologic
and immunological perspective) is represented by the actual
contribution of the LN to the induction, maintenance, and
perpetuation of the autoimmune response, with specific
reference to the activation of ACPA-positive B lymphocytes,
an RA-specific autoimmune trait related to a more severe
course of the disease and contributing to the upstream phases
of osteoclastogenesis [78, 79]. Despite the presence of B
cells and plasma cells reacting against citrullinated peptides
and being capable of spontaneous ACPA secretion ex vivo
has been proved in the inflamed synovium of patients with
established disease [80, 81], circulating ACPA are detectable
years before the clinical onset of the disease [78], and their
induction can take place before inflammatory changes in the
joints have established [17]. This supports the concept that
alternative/additional mechanisms and anatomic substrates
may contribute to the induction/perpetuation of autoim-
mune responses during the pathologic history of RA [10, 82,
83]. Notwithstanding the potential role of the bone marrow
[25, 28, 84] or the lung [85], both capable, as the synovium,
of inflammation-driven ectopic lymphoid tissue formation,
the physiological activity of secondary lymphoid tissues in
the generation of adaptive immune responses clearly points
at this compartment as a potentially critical site for both
the pre- and the postarthritic ACPA production process. On
the bases of these considerations, we may thus summarize
current research questions in the field into three simple but
critical points that still await to be convincingly addressed. (1)
Do conventional T cell-dependent GC reactions within sec-
ondary lymphoid tissues participate in ACPA-positive B cell
differentiation into ACPA-secreting plasma cells in course of
RA? (2) Which is the relative contribution of secondary lym-
phoid tissues versus ectopic inflammatory sites in this process
across progressive phases of the pathology (from pre-clinical
to established disease)? (3) Does the LN draining affected
joints play a primary role in the autoimmune response (as
proposed in animal models, see Section 4) if compared to
other (joint-unrelated) secondary lymphoid stations, such
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Figure 1: Potential pathophysiologic changes of and interactions between the joint and draining LN in course of inflammatory arthritis. (a)
Schematic representation of the main anatomic compartments within a noninflamed joint and a resting LN. (b) Hypothetical spectrum of
interactive relationships between the joint and the draining LN in course of arthritis. Joint inflammation promotes local accumulation of
immune cells, synovial tissue hypertrophy and structural damage through the differentiation/activation of osteoclasts. These changes can
promote increased fluid and cell drainage to adjoining LN through the afferent lymphatic system. An efficient drainage activity (left diagram,
blue-filled arrow) may exert a compensatory effect on joint pathology by promoting fluid and cell exit. As an additional (nonmutually
exclusive) effect, it might also contribute to disease immune-pathology by favouring neoantigen delivery, local immune-reactivity and
(auto)antibody production. In the left LN diagram of (b), these mechanisms, together with putative structural changes (hypertrophy, cell
accumulation, follicular hyperplasia, and increased vascularity) characterizing the challenged LN are shown. On the other side, a defective or
insufficient drainage activity to the node (right diagram, blue-dashed arrow) may directly contribute to accumulation of inflammatory cells
in the joint, promoting local cell activation and enhancing local disease (right hand side diagram of the joint).
as the spleen, mesenteric LN, and other mucosal associated
lymphoid tissues (MALT)?
Despite the assessment of these issues in humans still
faceing considerable technical challenges, it certainly rep-
resents a critical target for our full comprehension of the
disease and, hopefully, the conception of future therapeutic
reprogramming strategies. In this perspective, it is important
to emphasize that the LN not only acts as a site of con-
struction of adaptive immune responses, but also represents
a constitutive site of maintenance of peripheral tolerance.
Data supporting this concept derive from different studies
in mice and humans demonstrating the functional localiza-
tion in nodal cells of the transcription factors autoimmune
regulator (AIRE) and deformed epidermal autoregulatory
factor-1 (DEAF-1), molecules that physiologically mediate
autoreactive T cell deletion through the ectopic expression
of a broad spectrum of peripheral tissue-restricted antigens
(PTA) [86–89]. How these molecular systems operate in the
context of autoimmune lymphoid tissues, whether they are
involved in the process of tolerance disruption to citrullinated
peptides and other RA-associated autoantigens, and whether
they can be exploited for therapeutic purposes is currently
unclear.
6.2. Biomarker Development. Beside the importance of
understanding LN immunological behaviour, the same com-
partment may also be seen as a potential new source of
biomarkers. Despite the introduction of biological agents and
the optimization of clinical management (early diagnosis and
treatment, tight control of disease activity) have considerably
improved the outcomes and quality of life of patients with
RA, the disease still presents a high degree of variability in
terms of therapeutic response and radiographic progression.
Validated tools able to fully predict this variability, likely
determined by the intrinsic genetic and pathobiologic het-
erogeneity of the disease, are still missing, with consequent
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limitations in our possibility to define standard algorithms
in critical stages of the disease, such as the selection of the
appropriate approach in patients with early RA, the selection
of the appropriate biological agent in patients nonresponding
to conventional disease modifying antirheumatic drugs, and
the identification of patients achieving pharmacologically
induced clinical remission that can taper or suspend treat-
ment with maintenance of health.Though the synovial tissue
certainly represents the elective site for the definition of
reliable indices embedded in the pathologic process [12–
14], it is likely that future advancements in the field of
biomarker discovery might benefit from progressing through
the development of multiparameter modeling focused on
both pharmacogenomic indices as well as on pathobiologic
markers reflecting disease activity status in different compart-
ments [13], including relevant juxta-articular sites. While the
“juxta-articular perspective” has been intensively investigated
for what concerns the subchondral bone marrow and the
evaluation of bone marrow edema [27, 28], no data are
currently available regarding the significance of draining LN
assessment in large and well characterized clinical settings.
As inferred by recent data in animal models and in humans,
the draining LN could actually represent a relevant focus
in this perspective, due to its variable involvement, its
reactivity dynamics that may only partly overlap with joint
inflammation, as well as due to its compensatory function
through lymphatic drainage that could make it a comple-
mentary parameter for the integrated evaluation of local
disease. Notwithstanding the obvious technical and ethical
limitations in analyzing LN biology in large, consecutive
and unbiased patient cohorts, a process that is required
for biomarker validation in the human setting, there is
now growing evidence (discussed in Section 5) that cellular
[68, 69], structural, and functional [36] changes of the
draining LNs can be potentially captured and monitored in
RA. The implementation of repeatable imaging techniques
able to sensitively identify these modifications with higher
specificity and mini-invasive sampling approaches able to
safely provide comprehensive biological insights represent
therefore essential tasks for the translational development of
LN research in human disease.
7. Conclusions
Our conception of RA as a disease with exclusive syn-
ovial extrinsication has greatly expanded over the past
decades, with increasing awareness of the potential involve-
ment of several articular and extra-articular districts along
the time-line of RA development. Being the nerve centre
for the generation of immune responses and the regula-
tion of inflammatory processes, the lymphoid compartment
comes to primary attention within the complex patho-
genetic scenario of RA. Better understanding of the sys-
temic and local LN responses might help clarifying the
many uncertainties that still characterize the immunopatho-
logical features and clinical behaviour of chronic arthri-
tis.
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